Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRNA therapy takes on autoimmune diseases in early trial

NCT ID NCT06747156

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This early-phase study tests a new mRNA-based drug (ABO2203) designed to help control autoimmune diseases that haven't responded to standard treatments. About 66 adults with conditions like lupus or rheumatoid arthritis will receive the therapy to see if it is safe and shows signs of working. The goal is to reduce disease activity, but ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210000, China

    Contact

    Contact

  • Ruijin Hospital

    RECRUITING

    Shanghai, China

    Contact

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430022, China

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE DISEASES